Literature DB >> 15858195

Nucleophosmin in acute myelogenous leukemia.

Masao Nakagawa, Yoshihiro Kameoka, Ritsuro Suzuki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15858195     DOI： 10.1056/NEJM200504283521719

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  13 in total

Review 1.  Loading and unloading: orchestrating centrosome duplication and spindle assembly by Ran/Crm1.

Authors:  Anuradha S Budhu; Xin W Wang
Journal:  Cell Cycle       Date:  2005-11-20       Impact factor: 4.534

2.  Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia.

Authors:  Giovanni Roti; Roberto Rosati; Rossella Bonasso; Paolo Gorello; Daniela Diverio; Massimo Fabrizio Martelli; Brunangelo Falini; Cristina Mecucci
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

3.  Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.

Authors:  Justin Taylor; Maria Sendino; Alexander N Gorelick; Alessandro Pastore; Matthew T Chang; Alexander V Penson; Elena I Gavrila; Connor Stewart; Ella M Melnik; Florisela Herrejon Chavez; Lillian Bitner; Akihide Yoshimi; Stanley Chun-Wei Lee; Daichi Inoue; Bo Liu; Xiao J Zhang; Anthony R Mato; Ahmet Dogan; Michael G Kharas; Yuhong Chen; Demin Wang; Rajesh K Soni; Ronald C Hendrickson; Gorka Prieto; Jose A Rodriguez; Barry S Taylor; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2019-07-08       Impact factor: 39.397

4.  Oridonin induces NPM mutant protein translocation and apoptosis in NPM1c+ acute myeloid leukemia cells in vitro.

Authors:  Fei-Fei Li; Sha Yi; Lu Wen; Jing He; Li-Jing Yang; Jie Zhao; Ben-Ping Zhang; Guo-Hui Cui; Yan Chen
Journal:  Acta Pharmacol Sin       Date:  2014-06       Impact factor: 6.150

5.  Nucleophosmin is selectively deposited on mRNA during polyadenylation.

Authors:  Viswanathan Palaniswamy; Karen C M Moraes; Carol J Wilusz; Jeffrey Wilusz
Journal:  Nat Struct Mol Biol       Date:  2006-04-09       Impact factor: 15.369

Review 6.  Biological and clinical consequences of NPM1 mutations in AML.

Authors:  E M Heath; S M Chan; M D Minden; T Murphy; L I Shlush; A D Schimmer
Journal:  Leukemia       Date:  2017-01-23       Impact factor: 11.528

7.  Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia.

Authors:  Kateřina Kuželová; Barbora Brodská; Ota Fuchs; Marie Dobrovolná; Petr Soukup; Petr Cetkovský
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

Review 8.  Nucleo-cytoplasmic transport as a therapeutic target of cancer.

Authors:  Giovanni Luca Gravina; William Senapedis; Dilara McCauley; Erkan Baloglu; Sharon Shacham; Claudio Festuccia
Journal:  J Hematol Oncol       Date:  2014-12-05       Impact factor: 17.388

9.  Structural consequences of nucleophosmin mutations in acute myeloid leukemia.

Authors:  Charles G Grummitt; Fiona M Townsley; Christopher M Johnson; Alan J Warren; Mark Bycroft
Journal:  J Biol Chem       Date:  2008-05-29       Impact factor: 5.157

Review 10.  Targeting nucleocytoplasmic transport in cancer therapy.

Authors:  Richard Hill; Bastien Cautain; Nuria de Pedro; Wolfgang Link
Journal:  Oncotarget       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.